Cancer Biology & Genetics Program
The Tuomas Tammela Lab
The Tammela lab is interested in understanding the remarkable phenotypic heterogeneity of cancer cells within tumors. We approach this question using a combination of sophisticated genetically engineered mouse models, single-cell approaches, tracing and ablation of distinct tumor cell lineages, CRISPR-mediated gene regulation, and advanced imaging techniques. We utilize the exceptional resources developed by our MSK collaborators, such as organoids and xenografts, for the translation of our findings into new treatments for human cancer. Our goal is to discover pathways that drive distinct cellular phenotypes and to develop new therapeutic concepts aimed at reducing cellular heterogeneity in tumors.
Marjanovic ND, Hofree M, Chan JE, Canner D, Wu K, Trakala M, Hartmann GG, Smith OC, Kim JY, Evans KV, Hudson A, Ashenberg O, Porter CBM, Bejnood A, Subramanian A, Pitter K, Yan Y, Delorey T, Phillips DR, Shah N, Chaudhary O, Tsankov A, Hollmann T, Rekhtman N, Massion PP, Poirier JT, Mazutis L, Li R, Lee JH, Amon A, Rudin CM, Jacks T, Regev A, Tammela T. Emergence of a High-Plasticity Cell State during Lung Cancer Evolution. Cancer Cell, 38(2):229-246 (2020).
Tammela T, Sanchez-Rivera FJ, Malli-Cetinbas N, Joshi NS, Helenius K, Park YK, Azimi R, Wu K, Kerper NR, Wesselhoeft RA, Gu X, Schmidt L, Cornwall-Brady M, Yilmaz ÖH, Xue W, Katajisto P, Bhutkar A, and Jacks T. A Wnt-producing niche drives proliferative potential and progression in lung adenocarcinoma. Nature, 545:355-359 (2017).
Roper J*, Tammela T*, Cetinbas N, Akkad A, Almeqdadi M, Wu K, Sánchez-Rivera F, Rickelt S, Park Y, Liang X, Oberli M, Eng G, Roghanian A, Azimi R, Kedrin D., Neupane R., Beyaz S., Sicinska E.T., Bass A., Suarez Y., Yoo J., Chen L., Taylor M.S., Zukerberg L., Katajisto P., Lees J., Deshpande V., Chen J., Hynes R.O., Langer R., Bhutkar A.J., Jacks T., Yilmaz. Ö.H. Epithelial genome editing and orthotopic transplantation models of sequential mutagenesis in colorectal cancer. Nature Biotechnology, 3:569–576 (2017).
Tammela T*, Zarkada G*, Nurmi H, Jakobsson L, Heinolainen K, Tvorogov D, Zheng W, Franco CA, Murtomäki A, Aranda E, Miura N, Ylä-Herttuala S, Fruttiger M, Mäkinen T, Eichmann A, Pollard JW, Gerhardt H, and Alitalo K. VEGFR-3 controls tip to stalk conversion at vessel fusion sites by reinforcing Notch signaling. Nature Cell Biology, 13:1202-13 (2011).
Tuomas Tammela, MD, PhD
- Cancer biologist Tuomas Tammela investigates cellular heterogeneity in lung, pancreatic and colon cancers.
- Massachusetts Institute of Technology: Postdoctoral Fellowship
- University of Helsinki, Finland: MD, PhD
- Office Phone
- Cancer Biology & Genetics Program
- Fiona and Stanley Druckenmiller Center for Lung Cancer Research
- Center for Stem Cell Biology
- David M. Rubenstein Center for Pancreatic Cancer Research
- PhD Programs in Computational Biology & Medicine
- MD/PhD Program
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
- Rita Allen Foundation Scholar (2020)
- National Cancer Institute R37 MERIT Award (2020)
- American Cancer Society Scholar (2020)
- V Foundation Scholar (2019)
- National Cancer Institute K99/R00 Award (2017)
Lab News & Events
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Tuomas Tammela discloses the following relationships and financial interests:
Regeneron Pharmaceuticals, Inc.
Provision of Services
University of Helsinki
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.